Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (71-80 of 231) with videos related to

Pageof 24
Sort By:
Advances in Hematology|April 26, 2022
Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple MyelomaFrancisco-Javier Cepeda-Piorno, Esther González-García, Alba Méndez-Gallego, et al.
British Journal of Haematology|May 28, 2021
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapyHang Quach, Ajay Nooka, Olga Samoylova, et al.
Clinical and Translational Science|June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple MyelomaXiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
Blood|May 31, 2014
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myelomaBruno Paiva, Mauricio Chandia, Maria-Belen Vidriales, et al.
Blood|December 4, 2015
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myelomaNiels W C J van de Donk, Philippe Moreau, Torben Plesner, et al.
The Oncologist|February 28, 2016
The Changing Landscape of Smoldering Multiple Myeloma: A European PerspectiveJo Caers, Carlos Fernández de Larrea, Xavier Leleu, et al.
British Journal of Haematology|May 16, 2019
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 studyMaria-Victoria Mateos, Robert Z Orlowski, Enrique M Ocio, et al.
Haematologica|February 22, 2024
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myelomaMaria Victoria Mateos, Katja Weisel, Evangelos Terpos, et al.
European Journal of Haematology|December 20, 2007
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study GroupReyes Arranz, Eulogio Conde, Carlos Grande, et al.
Annals of Hematology|February 18, 2021
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA studyShinsuke Iida, Takayuki Ishikawa, Chang Ki Min, et al.
Pageof 24

Showing results (71-80 of 231) with videos related to

Sort By:
Pageof 24
Advances in Hematology|April 26, 2022
Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple MyelomaFrancisco-Javier Cepeda-Piorno, Esther González-García, Alba Méndez-Gallego, et al.
British Journal of Haematology|May 28, 2021
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapyHang Quach, Ajay Nooka, Olga Samoylova, et al.
Clinical and Translational Science|June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple MyelomaXiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
Blood|May 31, 2014
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myelomaBruno Paiva, Mauricio Chandia, Maria-Belen Vidriales, et al.
Blood|December 4, 2015
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myelomaNiels W C J van de Donk, Philippe Moreau, Torben Plesner, et al.
The Oncologist|February 28, 2016
The Changing Landscape of Smoldering Multiple Myeloma: A European PerspectiveJo Caers, Carlos Fernández de Larrea, Xavier Leleu, et al.
British Journal of Haematology|May 16, 2019
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 studyMaria-Victoria Mateos, Robert Z Orlowski, Enrique M Ocio, et al.
Haematologica|February 22, 2024
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myelomaMaria Victoria Mateos, Katja Weisel, Evangelos Terpos, et al.
European Journal of Haematology|December 20, 2007
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study GroupReyes Arranz, Eulogio Conde, Carlos Grande, et al.
Annals of Hematology|February 18, 2021
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA studyShinsuke Iida, Takayuki Ishikawa, Chang Ki Min, et al.
Pageof 24